Exome Asset Management LLC Decreases Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX)

Exome Asset Management LLC decreased its position in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 17.5% during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor owned 207,627 shares of the biopharmaceutical company's stock after selling 43,973 shares during the period. TG Therapeutics comprises 3.2% of Exome Asset Management LLC's portfolio, making the stock its 5th biggest position. Exome Asset Management LLC owned about 0.13% of TG Therapeutics worth $4,856,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of TGTX. Franklin Resources Inc. lifted its position in shares of TG Therapeutics by 3.8% in the third quarter. Franklin Resources Inc. now owns 128,985 shares of the biopharmaceutical company's stock worth $2,945,000 after purchasing an additional 4,756 shares in the last quarter. Synovus Financial Corp acquired a new position in shares of TG Therapeutics during the 3rd quarter worth about $465,000. Teachers Retirement System of The State of Kentucky bought a new position in shares of TG Therapeutics in the 3rd quarter valued at about $1,039,000. Neo Ivy Capital Management acquired a new stake in shares of TG Therapeutics in the third quarter valued at about $2,358,000. Finally, Barclays PLC raised its holdings in TG Therapeutics by 83.9% during the third quarter. Barclays PLC now owns 347,057 shares of the biopharmaceutical company's stock worth $8,117,000 after acquiring an additional 158,323 shares in the last quarter. Institutional investors and hedge funds own 58.58% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on TGTX shares. StockNews.com upgraded TG Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday. TD Cowen began coverage on shares of TG Therapeutics in a research note on Tuesday, October 29th. They issued a "buy" rating and a $50.00 target price for the company. JPMorgan Chase & Co. upped their price target on shares of TG Therapeutics from $30.00 to $43.00 and gave the stock an "overweight" rating in a research report on Monday, November 25th. HC Wainwright lifted their price objective on shares of TG Therapeutics from $49.00 to $55.00 and gave the company a "buy" rating in a research report on Tuesday, November 5th. Finally, The Goldman Sachs Group boosted their price objective on shares of TG Therapeutics from $20.00 to $22.00 and gave the stock a "neutral" rating in a research note on Tuesday, November 5th. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $40.67.

TG Therapeutics Stock Performance

TGTX stock traded up $1.33 during midday trading on Friday, reaching $32.02. 2,117,001 shares of the company were exchanged, compared to its average volume of 3,604,403. The firm has a market capitalization of $4.98 billion, a price-to-earnings ratio of -320.17 and a beta of 2.25. The business has a 50-day moving average price of $28.56 and a two-hundred day moving average price of $23.40. TG Therapeutics, Inc. has a one year low of $12.84 and a one year high of $36.84. The company has a debt-to-equity ratio of 1.27, a current ratio of 4.59 and a quick ratio of 3.91.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last announced its earnings results on Monday, November 4th. The biopharmaceutical company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.03 by ($0.01). The company had revenue of $83.90 million for the quarter, compared to the consensus estimate of $81.68 million. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The business's quarterly revenue was down 49.4% on a year-over-year basis. During the same period in the previous year, the firm posted $0.73 EPS. Equities research analysts forecast that TG Therapeutics, Inc. will post 0.17 EPS for the current year.

Insiders Place Their Bets

In other news, Director Sagar Lonial sold 5,000 shares of the firm's stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $30.44, for a total transaction of $152,200.00. Following the transaction, the director now directly owns 100,195 shares of the company's stock, valued at approximately $3,049,935.80. This trade represents a 4.75 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 10.50% of the company's stock.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.